Hybridoma technology is a new biotechnological approach for commercial production of

Hybridoma technology specifically generates monoclonal antibodies by fusing antibody‑producing B lymphocytes with immortal myeloma cells to create hybridoma cell lines that secrete a single, defined antibody specificity. These hybridomas can be cultured to provide continuous, homogeneous antibody production suitable for diagnostic, imaging and therapeutic applications, and enable large‑scale or commercial manufacture of monoclonal antibodies due to their stability and limitless production potential [2]. While monoclonal antibodies can be used to study or purify molecules like interferons, the technology itself is aimed at producing monoclonal (not polyclonal) antibodies as a biopharmaceutical product [2].

Sources

1. [1] https://pmc.ncbi.nlm.nih.gov/articles/PMC8521504/
2. [2] https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/hybridoma